To date, few examples of dissolution models for real-time release testing (RTRT) have been approved for commercial drug products or published in literature.
Atorvastatin (ATS) is widely used to treat high cholesterol and potentially lower the risk of cardiac complications.
The development of generic ophthalmic drug products is challenging due to the complexity of the ocular system, and a lack of sensitive testing to evaluate the interplay of physiology with ophthalmic formulations.
Students have an increased interest in learning physiologically based pharmacokinetic (PBPK) modeling, but this requires an in-depth understanding of biopharmaceutics and pharmacokinetics.
Chief executive officer Shawn O’Connor will be presenting at the Sidoti Fall Small Cap Investor Conference taking place virtually on September 21-22, 2022.
To develop a PBPK model for pyrotinib and qualify it with the in vivo data obtained after oral administrations.
Number of different processes contribute to net drug absorption
Dr. Brian P. Booth and Dr. Hao Zhu from the Office of Clinical Pharmacology (OCP) at the FDA will present and discuss Project Optimus, an initiative from the Oncology Center of Excellence (OCE) to reform the dose optimization and dose selection paradigm in oncology drug development.
Management will be presenting at Baird’s 2022 Global Healthcare Conference
Ketoprofen is registered in many countries for injectable administration in cattle.
Role of PBPK in Pediatric Drug Development
A physiologically based biopharmaceutics model (PBBM) was developed to mechanistically investigate the effect of formulation and food on selumetinib pharmacokinetics.
The majority of drug candidates exhibit weakly basic characteristics with high lipophilicity.
Increasingly-sophisticated parameter-sensitivity analysis techniques continue to be developed, and each technique...
Extensive data sharing with large pharmaceutical partner will expand property prediction space and improve model performance